Replies to post #110866 on Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

We have found evidence that eltroprazine has been studied in several clinical trials to date and has amassed safety data in several hundreds (the news release from Amarantus says 700) of subjects without serious adverse events that would impede future development

Eltoprazine's advantage over amantadine may be its duration of action and improved safety and tolerability. Amantadine has been associated with several central nervous system side effects, likely due to the drug's dopaminergic and adrenergic activity, and to a lesser extent, its activity as an anticholinergic. CNS side effects include nervousness, anxiety, agitation, insomnia, difficulty in concentrating, and exacerbations of pre-existing seizure disorders and psychiatric symptoms.]

http://seekingalpha.com/article/1944401-amarantus-licenses-phase-2b-ready-eltoprazine-for-pd-lid